Technology & Software Global On demand · 24-48h

Global Custom Adeno-Associated Virus (AAV) Services Market Strategic Research Report

Name: Global Custom Adeno-Associated Virus (AAV) Services Market Strategic Research Report
Brand: Market Research Reports, Inc.
Price: 3500 USD
Availability: PreOrder

Global Custom Adeno-Associated Virus (AAV) Services Market S…

$3,500 USD

Strategic Research Report

Global Custom Adeno-Associated Virus (AAV) Services Market

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Adherent Culture, Suspension Culture

By Application: Vaccine Development, Gene Therapy, Academic Scientific Research Institution, Others

Key Players: Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), CCRM, FUJIFILM Diosynth Biotechnologies, Biovian, Miltenyi Bioindustry, Aldevron, Takara Bio, Yposkesi, Genezen, Exthera, GenScript ProBio, EurekaBio, Obio Technology, GeneSail Biotech, VectorBuilder, WuXi ATU, Ubrigene, Porton Biologics, Pharmaron, PackGene Biotechnology

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2024 · forecast to 2032

Length: 172 pages

Обзор

Scope of the Report

Custom Adeno-Associated Virus (AAV) services refer to specialized biotechnological offerings that involve the design, production, and optimization of AAV vectors tailored to specific research or therapeutic needs. These services are typically provided by biotech companies or research institutions and are widely used in gene therapy, genetic research, and preclinical studies.

Custom AAV services are crucial for advancing gene therapy research and developing novel therapeutic approaches for genetic disorders. They provide researchers and clinicians with the tools needed to precisely manipulate gene expression in various cell types and tissues, facilitating the development of effective and targeted treatments.

Global key Custom Adeno-Associated Virus (AAV) Services players cover Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, etc.

This report presents a comprehensive overview of the global Custom Adeno-Associated Virus (AAV) Services market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

Adherent Culture
Suspension Culture

Segment by Application

Vaccine Development
Gene Therapy
Academic Scientific Research Institution
Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Custom Adeno-Associated Virus (AAV) Services market:

Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
Distributors, channel partners and end users in Vaccine Development, Gene Therapy, Academic Scientific Research Institution evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Segments covered in this report

By Type

Adherent CultureSuspension Culture

By Application

Vaccine DevelopmentGene TherapyAcademic Scientific Research InstitutionOthers

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Volume Analysis
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Application
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Type

3.1 Market Segmentation by Type
3.1.1 Market by Type Overview
3.1.2 Adherent Culture
3.1.3 Suspension Culture
3.1.4 Volume Analysis

04Market Segmentation by Application

4.1 Market Segmentation by Application
4.1.1 Market by Application Overview
4.1.2 Vaccine Development
4.1.3 Gene Therapy
4.1.4 Academic Scientific Research Institution
4.1.5 Others
4.1.6 Volume Analysis

05Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

06Country-Level Market Forecast

6.1 Asia Pacific
6.1.1 China
6.1.2 Japan
6.1.3 Korea
6.1.4 Southeast Asia
6.1.5 India
6.1.6 Australia
6.1.7 Rest of Asia Pacific
6.2 North America
6.2.1 United States
6.2.2 Canada
6.2.3 Mexico
6.2.4 Rest of North America
6.3 Europe
6.3.1 Germany
6.3.2 France
6.3.3 UK
6.3.4 Italy
6.3.5 Russia
6.3.6 Rest of Europe
6.4 Middle East & Africa
6.4.1 Egypt
6.4.2 South Africa
6.4.3 Israel
6.4.4 Turkey
6.4.5 GCC Countries
6.4.6 Rest of Middle East & Africa
6.5 Latin America
6.5.1 Brazil
6.5.2 Rest of Latin America

07Growth Drivers & Inhibitors

7.1 Growth Drivers & Inhibitors
7.1.1 Section Overview
7.1.2 Growth Drivers
7.1.3 Growth Inhibitors
7.1.4 Driver and Inhibitor Impact Assessment
7.1.5 Analyst Perspective

08Key Company Profiles

8.1 Thermo Fisher Scientific
8.1.1 Company Overview
8.1.2 Key Products & Segments
8.1.3 Financial Performance (2023–2025)
8.1.4 Business Strategy
8.1.5 SWOT Analysis
8.1.6 Strategic Implications (2026–2032)
8.2 Lonza
8.2.1 Company Overview
8.2.2 Key Products & Segments
8.2.3 Financial Performance (2023–2025)
8.2.4 Business Strategy
8.2.5 SWOT Analysis
8.2.6 Strategic Implications (2026–2032)
8.3 Catalent
8.3.1 Company Overview
8.3.2 Key Products & Segments
8.3.3 Financial Performance (2023–2025)
8.3.4 Business Strategy
8.3.5 SWOT Analysis
8.3.6 Strategic Implications (2026–2032)
8.4 Charles River
8.4.1 Company Overview
8.4.2 Key Products & Segments
8.4.3 Financial Performance (2023–2025)
8.4.4 Business Strategy
8.4.5 SWOT Analysis
8.4.6 Strategic Implications (2026–2032)
8.5 Merck
8.5.1 Company Overview
8.5.2 Key Products & Segments
8.5.3 Financial Performance (2023–2025)
8.5.4 Business Strategy
8.5.5 SWOT Analysis
8.5.6 Strategic Implications (2026–2032)
8.6 SK pharmteco
8.6.1 Company Overview
8.6.2 Key Products & Segments
8.6.3 Financial Performance (2023–2025)
8.6.4 Business Strategy
8.6.5 SWOT Analysis
8.6.6 Strategic Implications (2026–2032)
8.7 Oxford Biomedica
8.7.1 Company Overview
8.7.2 Key Products & Segments
8.7.3 Financial Performance (2023–2025)
8.7.4 Business Strategy
8.7.5 SWOT Analysis
8.7.6 Strategic Implications (2026–2032)
8.8 AGC Biologics（MolMed）
8.8.1 Company Overview
8.8.2 Key Products & Segments
8.8.3 Financial Performance (2023–2025)
8.8.4 Business Strategy
8.8.5 SWOT Analysis
8.8.6 Strategic Implications (2026–2032)
8.9 Gene Universal
8.9.1 Company Overview
8.9.2 Key Products & Segments
8.9.3 Financial Performance (2023–2025)
8.9.4 Business Strategy
8.9.5 SWOT Analysis
8.9.6 Strategic Implications (2026–2032)
8.10 Polyplus (Sartorius)
8.10.1 Company Overview
8.10.2 Key Products & Segments
8.10.3 Financial Performance (2023–2025)
8.10.4 Business Strategy
8.10.5 SWOT Analysis
8.10.6 Strategic Implications (2026–2032)
8.11 CCRM
8.11.1 Company Overview
8.11.2 Key Products & Segments
8.11.3 Financial Performance (2023–2025)
8.11.4 Business Strategy
8.11.5 SWOT Analysis
8.11.6 Strategic Implications (2026–2032)
8.12 FUJIFILM Diosynth Biotechnologies
8.12.1 Company Overview
8.12.2 Key Products & Segments
8.12.3 Financial Performance (2023–2025)
8.12.4 Business Strategy
8.12.5 SWOT Analysis
8.12.6 Strategic Implications (2026–2032)
8.13 Biovian
8.13.1 Company Overview
8.13.2 Key Products & Segments
8.13.3 Financial Performance (2023–2025)
8.13.4 Business Strategy
8.13.5 SWOT Analysis
8.13.6 Strategic Implications (2026–2032)
8.14 Miltenyi Bioindustry
8.14.1 Company Overview
8.14.2 Key Products & Segments
8.14.3 Financial Performance (2023–2025)
8.14.4 Business Strategy
8.14.5 SWOT Analysis
8.14.6 Strategic Implications (2026–2032)
8.15 Aldevron
8.15.1 Company Overview
8.15.2 Key Products & Segments
8.15.3 Financial Performance (2023–2025)
8.15.4 Business Strategy
8.15.5 SWOT Analysis
8.15.6 Strategic Implications (2026–2032)
8.16 Takara Bio
8.16.1 Company Overview
8.16.2 Key Products & Segments
8.16.3 Financial Performance (2023–2025)
8.16.4 Business Strategy
8.16.5 SWOT Analysis
8.16.6 Strategic Implications (2026–2032)
8.17 Yposkesi
8.17.1 Company Overview
8.17.2 Key Products & Segments
8.17.3 Financial Performance (2023–2025)
8.17.4 Business Strategy
8.17.5 SWOT Analysis
8.17.6 Strategic Implications (2026–2032)
8.18 Genezen
8.18.1 Company Overview
8.18.2 Key Products & Segments
8.18.3 Financial Performance (2023–2025)
8.18.4 Business Strategy
8.18.5 SWOT Analysis
8.18.6 Strategic Implications (2026–2032)
8.19 Exthera
8.19.1 Company Overview
8.19.2 Key Products & Segments
8.19.3 Financial Performance (2023–2025)
8.19.4 Business Strategy
8.19.5 SWOT Analysis
8.19.6 Strategic Implications (2026–2032)
8.20 GenScript ProBio
8.20.1 Company Overview
8.20.2 Key Products & Segments
8.20.3 Financial Performance (2023–2025)
8.20.4 Business Strategy
8.20.5 SWOT Analysis
8.20.6 Strategic Implications (2026–2032)
8.21 EurekaBio
8.21.1 Company Overview
8.21.2 Key Products & Segments
8.21.3 Financial Performance (2023–2025)
8.21.4 Business Strategy
8.21.5 SWOT Analysis
8.21.6 Strategic Implications (2026–2032)
8.22 Obio Technology
8.22.1 Company Overview
8.22.2 Key Products & Segments
8.22.3 Financial Performance (2023–2025)
8.22.4 Business Strategy
8.22.5 SWOT Analysis
8.22.6 Strategic Implications (2026–2032)
8.23 GeneSail Biotech
8.23.1 Company Overview
8.23.2 Key Products & Segments
8.23.3 Financial Performance (2023–2025)
8.23.4 Business Strategy
8.23.5 SWOT Analysis
8.23.6 Strategic Implications (2026–2032)
8.24 VectorBuilder
8.24.1 Company Overview
8.24.2 Key Products & Segments
8.24.3 Financial Performance (2023–2025)
8.24.4 Business Strategy
8.24.5 SWOT Analysis
8.24.6 Strategic Implications (2026–2032)
8.25 WuXi ATU
8.25.1 Company Overview
8.25.2 Key Products & Segments
8.25.3 Financial Performance (2023–2025)
8.25.4 Business Strategy
8.25.5 SWOT Analysis
8.25.6 Strategic Implications (2026–2032)
8.26 Ubrigene
8.26.1 Company Overview
8.26.2 Key Products & Segments
8.26.3 Financial Performance (2023–2025)
8.26.4 Business Strategy
8.26.5 SWOT Analysis
8.26.6 Strategic Implications (2026–2032)
8.27 Porton Biologics
8.27.1 Company Overview
8.27.2 Key Products & Segments
8.27.3 Financial Performance (2023–2025)
8.27.4 Business Strategy
8.27.5 SWOT Analysis
8.27.6 Strategic Implications (2026–2032)
8.28 Pharmaron
8.28.1 Company Overview
8.28.2 Key Products & Segments
8.28.3 Financial Performance (2023–2025)
8.28.4 Business Strategy
8.28.5 SWOT Analysis
8.28.6 Strategic Implications (2026–2032)
8.29 PackGene Biotechnology
8.29.1 Company Overview
8.29.2 Key Products & Segments
8.29.3 Financial Performance (2023–2025)
8.29.4 Business Strategy
8.29.5 SWOT Analysis
8.29.6 Strategic Implications (2026–2032)

09Competitive Landscape

9.1 Competitive Landscape Overview
9.2 Competitive Intensity Assessment
9.3 Key Player Strategies & Positioning
9.4 Competitive Dynamics & Strategic Outlook
9.4.1 Emerging Competitive Threats
9.4.2 Consolidation vs. Fragmentation Outlook
9.4.3 Competitive Response Matrix
9.4.4 Strategic Recommendations, 2026–2032

10Porter's Five Forces Analysis

10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry

11PESTLE Analysis

11.1 Political
11.2 Economic
11.3 Social and Demographic
11.4 Technological
11.5 Legal and Regulatory
11.6 Environmental
11.7 Strategic Implications of the PESTLE Assessment

12SWOT Analysis

13Future Trends & Outlook

13.1 Future Trends & Outlook
13.1.1 Trend Summary and Commercial Maturity Assessment
13.1.2 Technology and Innovation Trends
13.1.3 Long-Term Market Outlook
13.1.4 Investment & M&A Activity Outlook
13.1.5 Overall Outlook Assessment

Frequently asked questions

What is Custom Adeno-Associated Virus (AAV) Services?

What are the main segments of the Custom Adeno-Associated Virus (AAV) Services market by type?

By type, the market is segmented into Adherent Culture and Suspension Culture.

Which applications drive demand in the Custom Adeno-Associated Virus (AAV) Services market?

Key applications covered include Vaccine Development, Gene Therapy, Academic Scientific Research Institution and Others.

Who are the key players in the Custom Adeno-Associated Virus (AAV) Services market?

Key players profiled include Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica and AGC Biologics（MolMed）, among 29 companies covered in total.

Which regions and countries are covered for Custom Adeno-Associated Virus (AAV) Services?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.

Who should buy the Custom Adeno-Associated Virus (AAV) Services market report?

The report is intended for manufacturers and solution providers, distributors and end users in Vaccine Development, Gene Therapy and Academic Scientific Research Institution, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Custom Adeno-Associated Virus (AAV) Services market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.